Affimed successfully completes preclinical development of AFM 13

(Thomson Reuters ONE) - Affimed Therapeutics AG / Affimed successfully completes preclinical development of AFM 13 processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. Heidelberg, Germany; February 08 2010: Affimed Therapeutics AG, the therapeuticTandAb antibody company, today announced the successful completion of thepreclinical development of its lead product AFM 13 for the treatment ofHodgkin's lymphoma. Following promising preclinical data the company is nowpreparing the start of its first clinical study with AFM 13.Preclinical pharmacology, pharmacokinetic and toxicology data have shown strongevidence for the tolerability and efficacy of AFM 13 to treat Hodgkin'slymphoma. Several studies with cynomolgus monkeys confirmed a good tolerabilityof the TandAb. No clinical toxicities were observed.During the preclinical development of AFM 13 a robust GMP manufacturing processwith a stable formulation was established. The generated clinical material isnow ready for clinical development. Stability tests on the produced charges areongoing.AFM 13 is an innovative bispecific antibody based on the company's proprietaryTandAb technology. TandAbs are tetravalent antibodies with manifold applicationpossibilities. In the oncology indications TandAbs bind target molecules on thesurface of tumor cells and simultaneously activate T cells or natural killercells (NK cells). TandAbs are able to identify and selectively destroy tumorcells in the human body.Dr. Rolf H. G?er, CEO of Affimed, commented: "This successful preclinicalprogram adds a further important milestone to the development of our leadproduct and provides further validation of our technology platform. AFM 13 isthe first TandAb antibody to enter clinical development from a pipeline of ownpreclinical TandAb candidates. The strong evidence of tolerability and efficacyin treating Hodgkin's lymphoma will be further verified through clinical trials.IND and IMPD filings will be submitted soon."For further information please contact:Affimed Therapeutics AGDr. Rolf H. G?er (CEO)Phone: +49 6221 65307-0Fax: +49 6221 65307 77E-Mail:R.Guenther(at)affimed.com MC Services AGBirte SteinPhone: +49 89 210 228 12Fax: +49 89 210 228 88E-Mail:Birte.Stein(at)mc-services.eu About Affimed Therapeutics AG:Affimed Therapeutics AG is a therapeutic antibody company developing uniqueantibody therapeutics as novel treatments for life threatening diseases withhigh unmet medical need. The company has been generating a growing pipeline ofanticancer drug candidates based on its proprietary TandAb technology platform.Affimed's lead product candidate AFM 13 for the treatment of Hodgkin's diseasehas successfully completed preclinical development and will enter clinicalstudies in early 2010. Both AFM 11 and AFM 12 to treat Non-Hodgkin's lymphomaare currently in preclinical development and are expected to begin clinicalstudies in late 2010. Further novel product candidates are being developed forthe treatment of solid tumors, autoimmune diseases and asthma.  Affimed'sproprietary and highly productive TandAb technology enables the company togenerate unique tetravalent, bispecific, fully human antibody formats thatpromise increased therapeutic potential and superior profiles compared tomonoclonal antibodies. The private company Affimed, which employs 26 people inHeidelberg, is a spin-off from the German Cancer Research Centre (DKFZ),Heidelberg.[HUG#1381356] --- End of Message --- Affimed Therapeutics AGIm Neuenheimer Feld 582 Heidelberg Germany Press release (PDF): http://hugin.info/142251/R/1381356/340644.pdf

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Leseranfragen:
PresseKontakt / Agentur:
Bereitgestellt von Benutzer: hugin
Datum: 08.02.2010 - 03:00 Uhr
Sprache: Deutsch
News-ID 1010084
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

Heidelberg

Phone:

Kategorie:

Business News

Anmerkungen:


Diese Pressemitteilung wurde bisher 117 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Affimed successfully completes preclinical development of AFM 13
"
steht unter der journalistisch-redaktionellen Verantwortung von

Affimed Therapeutics AG (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Alle Meldungen von Affimed Therapeutics AG